Theralase Technologies Inc. V.TLT

Market valuation example

[ScienceFirst]

Partial response and shrinking tumors.  Not destroying them like us.

 

Market valuation = 992MM$US.  

Highest valuation: 1.4B$US (Jan. 2022)

 

Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract) - Merus

 

The analysis included 83 patients out of 110, with efficacy determined in 79 who were eligible for an assessment as of the April 12 cutoff date. Merus found that zeno led to tumor shrinkage in 70% of patients and clocked a median response duration of 9.1 months. 20 out of the 83 total patients (24%) were continuing on treatment as of the cutoff date. The median time to response was 1.8 months and median duration of exposure was 6.3 months.

 

 

Merus - Corporate presentation

[Infinity]

Hey Sci-Fi,  Thanks for the highlights of this.  The median response duration is stated at 9.1 months.  What happens after the response wears off.  Does the turmor remain in the shrunken state or does it begin to grow or multiple.. Another question "20 of the 83 patients (24%) were continuing on treatment."  I assume the reasoning could be that tumor could